Partnerships for Next Generation Biologics
Partnering for Success
Ambrx works with partners to make better antibody conjugates, therapeutic peptides and bi-specifics. These partnerships allow pharmaceutical and biotechnology companies to discover and optimize their drug candidates by using Protein Medicinal Chemistry™. Ambrx is dedicated to creating exceptional collaborations focused on breakthrough technologies that deliver next-generation, protein-based medicines.
Astellas Pharma Inc.
In April of 2013, Astellas Pharma Inc. entered into a collaboration with Ambrx Inc. for the discovery and development of novel antibody drug conjugates (ADCs). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high potency and a wider therapeutic index than ADCs created using conventional non-specific conjugation.
In September of 2011, Ambrx entered into a worldwide collaboration with Bristol-Myers Squibb to develop and commercialize product candidates surrounding the Fibroblast Growth Factor 21 (FGF-21) protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure. Derivatives of FGF-21 and Relaxin were developed using Ambrx’s unique ReCODE™ platform technology to modify the native proteins with amino acid building blocks beyond the 20 naturally occurring amino acids. Bristol-Myers Squibb and Ambrx also entered into research collaborations for both programs, which focus on engineering enhanced versions of the two target proteins for therapeutic use. In May of 2013, Ambrx entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrx’s Protein Medicinal Chemistry™ technology. These drug candidates will be based on Ambrx’s EuCODE™ technology.
In January 2007, we entered into a collaborative research, license and commercialization agreement with Eli Lilly, pursuant to which we work with Eli Lilly’s Elanco Animal Health division to discover, develop and commercialize a broad portfolio of Ambrx-enabled bio-conjugates for animal health. In February 2011 this agreement was amended. Under this agreement, as amended to date, we granted Eli Lilly an exclusive, worldwide license to utilize certain of our drug technology, trade secrets, know-how, patent rights and inventions to develop and commercialize certain product candidates in the field of animal health, as well as human and non- human food safety applications.
Zhejiang Medicine Co., Ltd.
In June of 2013 Ambrx entered into a collaboration with Zhejiang Medicine Co., Ltd. to develop and commercialize ARX788, Ambrx’s most advanced internally developed site-specific ADC targeting HER2-positive breast cancer. Under the agreement, Ambrx and ZMC will continue the development of ARX788. ZMC received commercial rights in China while Ambrx retained commercial rights outside of China and receives royalties on sales of the product in China.